Sana reported no meaningful revenue across most quarters, with operating losses reaching $95.0 million in 2025Q2 and R&D expense ranging from $24.0 million to $54.6 million per quarter, so cost trajectory rather than sales momentum drives results.
Sana Biotechnology, Inc. (SANA) annual income statement — 8-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 2.39M | 12.75M | 0 | 0 | 0 | 0 | 10.17M | 3.92M | 1K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -2.39M | -12.75M | 0 | 0 | 0 | 0 | -10.17M | -3.92M | -1K |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | 100% | -159.4% | - | - |
| Operating Expenses | 143.59M | 178.21M | 272.72M | 293.14M | 272.56M | 356.91M | 150.95M | 141.15M | 8.22M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 45.37M | 44.3M | 64.04M | 73.3M | 71.56M | 50.41M | 28.27M | 21.78M | 4.21M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 161.6M | 131.98M | 208.68M | 219.84M | 201M | 306.5M | 122.68M | 119.38M | 4.01M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -1000K | 1.93M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -145.98M | -190.96M | -272.72M | -293.14M | -272.56M | -356.91M | -161.12M | -141.15M | -8.22M |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 29.98% | 6.97% | -7.55% | 23.63% | -121.51% | -14.15% | -1616.97% | - |
| EBITDA | -130.27M | -178.21M | -257.22M | -268.58M | -256.94M | -345.84M | -155.2M | -139.33M | -8.22M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 42% | 30.72% | 4.23% | -4.53% | 25.71% | -122.83% | -11.39% | -1594.96% | - |
| D&A (Non-Cash Add-back) | 15.71M | 12.75M | 15.5M | 24.56M | 15.63M | 11.07M | 5.92M | 1.83M | 1K |
| EBIT | -149.27M | -244.17M | -266.76M | -283.25M | -269.48M | -355.93M | -297.2M | -142.82M | -13.25M |
| Net Interest Income | 1.73M | 3.85M | 10.47M | 9.94M | 3.76M | 676K | 747K | 2.86M | 0 |
| Interest Income | 1.73M | 3.85M | 10.47M | 9.94M | 3.76M | 676K | 747K | 2.86M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -3.29M | -53.21M | 5.96M | 9.89M | 3.09M | 981K | -136.08M | 2.83M | -5.03M |
| Pretax Income | -149.27M | -244.17M | -266.76M | -283.25M | -269.48M | -355.93M | -297.2M | -138.32M | -13.25M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | -11.9M | -7.55M | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 4% | 5.46% | 0% |
| Net Income | -149.27M | -244.17M | -266.76M | -283.25M | -269.48M | -355.93M | -285.31M | -130.78M | -13.25M |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 36.32% | 8.47% | 5.82% | -5.11% | 24.29% | -24.75% | -118.16% | -887.23% | - |
| Net Income (Continuing) | -149.27M | -244.17M | -266.76M | -283.25M | -269.48M | -355.93M | -285.31M | -130.78M | -13.25M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.48 | -0.96 | -1.16 | -1.46 | -1.43 | -2.14 | -1.63 | -0.70 | -0.07 |
| EPS Growth % | 46.39% | 17.24% | 20.55% | -2.1% | 33.18% | -31.29% | -132.86% | -890.1% | - |
| EPS (Basic) | - | -0.96 | -1.16 | -1.46 | -1.43 | -2.14 | -1.63 | -0.70 | -0.07 |
| Diluted Shares Outstanding | 308.79M | 253.23M | 230.89M | 194.54M | 188.34M | 166.43M | 187.51M | 187.34M | 187.34M |
| Basic Shares Outstanding | 307M | 253.23M | 230.89M | 194.54M | 188.34M | 166.43M | 187.51M | 187.34M | 187.34M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying SANA stock.
For fiscal year 2025, Sana Biotechnology, Inc. (SANA) reported total revenue of $0.0M.
Sana Biotechnology, Inc. (SANA) reported a net loss of $244.2M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Liquidity runway constraint
Metrics are mathematically derived from official filings.
Pre-Revenue Status Limits Growth Assessment
Based on reported figures, Sana generated no meaningful revenue across most recent quarters, with only a $2.4 million COGS line appearing in 2026Q1, leaving revenue growth analysis largely unavailable and the trajectory driven by expense timing rather than sales momentum.
The income statement shows revenue as blank for every reported quarter, so the standard growth trend cannot be assessed and no conclusion about revenue durability should be drawn from the data. The 2026Q1 COGS entry without matching revenue suggests cost recognition ahead of any sales base, which warrants investigation of the underlying accounting treatment. Investors should treat trajectory here as a function of R&D spending cadence rather than commercial traction.
Operating Losses Driven by R&D Intensity
As reported in financial statements, Sana's R&D expense ranged from $24.0 million to $54.6 million per quarter, with operating losses of up to $95.0 million in 2025Q2, indicating that the cost base is set by clinical program scale rather than revenue.
Because operating income tracks R&D nearly one-for-one, there is no evidence of operating leverage in the conventional sense, as the business has no gross profit base to scale against. SG&A remained comparatively stable between $10.3 million and $17.3 million per quarter, suggesting overhead has not expanded in step with R&D. Investors should monitor whether R&D spending moderates as programs advance, since that is the primary lever on the loss trajectory.
Positive Quarter Reflects Non-Operating Swing
Based on Sana's reported figures, the 2026Q3 net income of $20.4 million turned positive despite an operating income of $18.5 million, a result that may reflect non-operating items warranting closer examination.
The 2026Q3 EPS of $0.07 arrives after several quarters of losses averaging roughly $0.20 per share, and the single positive quarter should not be extrapolated into a profitability trend. Stock-based compensation of $5.3 million to $11.4 million per quarter is a material non-cash charge that depresses reported losses differently from cash burn. The reconciliation between operating and net income in 2026Q3 appears to be the key item to verify in the filing.
R&D Dominates a Non-Discretionary Cost Base
According to recent SEC filings, Sana's R&D expense of $33.9 million in 2026Q3 against SG&A of $10.9 million shows that roughly three-quarters of operating spend is directed at clinical development rather than overhead.
The cost structure is concentrated in R&D, which is largely non-discretionary if the company intends to advance SC291, SC451 and related programs through the clinical pipeline. SG&A has remained within a narrow band, which suggests disciplined overhead management relative to program spending. Investors should view continued R&D intensity as consistent with the stated development strategy while recognizing it sets a high baseline burn rate.
Cash Runway Risk Overshadows Loss Narrowing
Based on reported figures, Sana's $71.87 million cash position against quarterly operating losses frequently exceeding $40 million suggests a limited runway that could force dilutive financing before clinical milestones are reached.
The single profitable quarter in 2026Q3 does not offset a pattern of recurring operating losses, and a short-seller would likely argue that the positive EPS is a non-recurring artifact rather than an inflection. With a Debt-to-Equity ratio of 0.49 and reported ROE of -118.7%, the balance sheet offers limited cushion against further losses. This suggests a meaningful probability of equity issuance at unfavorable valuations, which warrants further investigation as the next filings are reviewed.